The biological functions and clinical applications of exosomes in lung cancer

被引:0
作者
Rui Chen
Xin Xu
Zijun Qian
Congcong Zhang
Yongjie Niu
Zhixian Wang
Jianli Sun
Xiao Zhang
Yongchun Yu
机构
[1] Shanghai University of Traditional Chinese Medicine,Shanghai Municipal Hospital of Traditional Chinese Medicine
[2] Shanghai Jiao Tong University,Shanghai Chest Hospital
[3] Longhua Hospital Shanghai University of Traditional Chinese Medicine,Department of Oncology
来源
Cellular and Molecular Life Sciences | 2019年 / 76卷
关键词
Lung cancer; Exosomes; Biomarkers; Immunotherapy; Drug delivery vehicles;
D O I
暂无
中图分类号
学科分类号
摘要
Lung cancer remains the leading cause of cancer-related death worldwide, and the high incidence rates are worrisome. Exosomes are a class of extracellular vesicles secreted by most cells, including RNAs, proteins and lipids. Exosomes can mediate cell-to-cell communication in both physiologic and pathologic processes. Accumulated evidences show that cancer-derived exosomes aid in the recruitment and reprogramming of constituents correlated with tumor microenvironment. Furthermore, exosome-based clinical trials have been completed in advanced lung cancer patients. In this review, we discuss the roles of exosomes in a lung cancer microenvironment, such as its participation in lung cancer initiation, progression and metastasis as well as being involved in angiogenesis, epithelial–mesenchymal transition (EMT), immune escape, and drug resistance. In addition, we focus on the potential of exosomes as diagnostic and prognostic biomarkers in lung cancer, as well as the challenges faced by and advantages of exosomes as drug delivery vehicles and in exosome-based immunotherapy.
引用
收藏
页码:4613 / 4633
页数:20
相关论文
共 1751 条
[1]  
Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 359 1367-1380
[2]  
Ferlay J(2008)Lung cancer N Engl J Med 353 123-132
[3]  
Soerjomataram I(2005)Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 361 947-957
[4]  
Siegel RL(2009)Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 362 2380-2388
[5]  
Torre LA(2010)Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 17 577-589
[6]  
Jemal A(2016)Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial Lancet Oncol 378 113-125
[7]  
Herbst Roy S(2018)Osimertinib in untreated EGFR-mutated advanced non-small-cell Lung cancer N Engl J Med 363 1693-1703
[8]  
Heymach JV(2010)Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N Engl J Med 355 2542-2550
[9]  
Lippman SM(2006)Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 372 2018-2028
[10]  
Shepherd FA(2015)Pembrolizumab for the treatment of non-small-cell lung cancer N Engl J Med 387 1540-1550